Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | review

Is dosing in oncology gender-sensitive?

verfasst von: MD Christine Marosi

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Cancer is still the second cause of death in Europe and with the aging of populations, the number of cancer patients will further increase. For Austria, the gender-specific analysis of epidemiology and survival rates of cancer in the past 10 years show that there are significant differences between men and women that could at least partly been used for the implementation of future preventive and/or therapeutic actions. Gender-specific pharmacokinetic differences for medications with narrow therapeutic index as most of the drugs used in cancer therapy have been documented for more than a decade. It would be very helpful to develop instruments allowing individualized treatment planning taking into account the age, function of relevant organs, and gender of the patient than to adhere indefinitely to body surface area.
Literatur
1.
Zurück zum Zitat Malvezzi M, et al. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6. Malvezzi M, et al. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.
2.
Zurück zum Zitat Bosetti C, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71. CrossRefPubMed Bosetti C, et al. Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657–71. CrossRefPubMed
5.
Zurück zum Zitat Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14(9):2590–611. PubMed Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14(9):2590–611. PubMed
6.
Zurück zum Zitat Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82(4):323–5. CrossRefPubMed Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst. 1990;82(4):323–5. CrossRefPubMed
7.
Zurück zum Zitat Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19(2):171–7. CrossRefPubMed Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001;19(2):171–7. CrossRefPubMed
8.
Zurück zum Zitat Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17(Chicago):863–71. CrossRef Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17(Chicago):863–71. CrossRef
9.
10.
Zurück zum Zitat Deeg HJ, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transpl. 1995;15(3):461–8. Deeg HJ, et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transpl. 1995;15(3):461–8.
11.
Zurück zum Zitat Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329–42. CrossRefPubMed Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41(5):329–42. CrossRefPubMed
12.
Zurück zum Zitat Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37(11):529–47. PubMed Beierle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther. 1999;37(11):529–47. PubMed
13.
Zurück zum Zitat Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339–46. CrossRefPubMed Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24(5):339–46. CrossRefPubMed
14.
Zurück zum Zitat Wasan KM, Kwong M. Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Pharmacol Toxicol. 1997;80(6):301–7. CrossRefPubMed Wasan KM, Kwong M. Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Pharmacol Toxicol. 1997;80(6):301–7. CrossRefPubMed
15.
Zurück zum Zitat Marazziti D, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27. CrossRefPubMed Marazziti D, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27. CrossRefPubMed
16.
Zurück zum Zitat Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol. 2012;214:411–42. CrossRefPubMed Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases. Handb Exp Pharmacol. 2012;214:411–42. CrossRefPubMed
17.
Zurück zum Zitat Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. CrossRefPubMed Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. CrossRefPubMed
18.
Zurück zum Zitat Koren G, Nordeng H, MacLeod S. Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther. 2013;93(3):260–2. CrossRefPubMed Koren G, Nordeng H, MacLeod S. Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther. 2013;93(3):260–2. CrossRefPubMed
19.
Zurück zum Zitat Al-Khatib T, et al. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913–9. CrossRefPubMed Al-Khatib T, et al. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913–9. CrossRefPubMed
20.
Zurück zum Zitat Grunberg SM, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33. CrossRefPubMed Grunberg SM, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33. CrossRefPubMed
21.
Zurück zum Zitat Plunkett RJ, et al. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg. 1999;90(6):1072–7. CrossRefPubMed Plunkett RJ, et al. Hormonal effects on glioblastoma multiforme in the nude rat model. J Neurosurg. 1999;90(6):1072–7. CrossRefPubMed
22.
Zurück zum Zitat Yates AJ, et al. Sex- and age-related differences in ceramide dihexosides of primary human brain tumors. Lipids. 1999;34(1):1–4. CrossRefPubMed Yates AJ, et al. Sex- and age-related differences in ceramide dihexosides of primary human brain tumors. Lipids. 1999;34(1):1–4. CrossRefPubMed
23.
Zurück zum Zitat Hodi FS, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5(9):557–61. CrossRefPubMed Hodi FS, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008;5(9):557–61. CrossRefPubMed
24.
Zurück zum Zitat Jager U, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–8. CrossRefPubMedCentralPubMed Jager U, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–8. CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Cabanillas F, et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17(9):1424–7. CrossRefPubMed Cabanillas F, et al. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol. 2006;17(9):1424–7. CrossRefPubMed
26.
Zurück zum Zitat Tarella C, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814–24. CrossRefPubMed Tarella C, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814–24. CrossRefPubMed
27.
Zurück zum Zitat Jatoi A, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–3. CrossRefPubMedCentralPubMed Jatoi A, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–3. CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg. 2009;208(2):269–78. CrossRefPubMed Kingham TP, Pachter HL. Colonic anastomotic leak: risk factors, diagnosis, and treatment. J Am Coll Surg. 2009;208(2):269–78. CrossRefPubMed
29.
Zurück zum Zitat Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008;20(1):104–11. CrossRefPubMed Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008;20(1):104–11. CrossRefPubMed
30.
Zurück zum Zitat Lee JP, et al. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30. CrossRefPubMedCentralPubMed Lee JP, et al. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30. CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat van der Veldt AA, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259–65. CrossRefPubMedCentralPubMed van der Veldt AA, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259–65. CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. CrossRefPubMed Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. CrossRefPubMed
33.
Zurück zum Zitat Shiba S, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014. doi:10.111/hep12297 [Epub ahead of print] Shiba S, et al. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatol Res. 2014. doi:10.111/hep12297 [Epub ahead of print]
34.
Zurück zum Zitat Rapoport BL, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423–31. Rapoport BL, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423–31.
Metadaten
Titel
Is dosing in oncology gender-sensitive?
verfasst von
MD Christine Marosi
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0178-0

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe